The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-founder and managing director Sander Slootweg says there’s still more that can be done to fund future European innovations and improve Europe’s competitiveness globally.
“We’ve observed in Europe that although we see great science, and we’ve been able to build great companies, in terms of the absolute magnitude of the ecosystem, we’re still lagging behind the U.S., and also China is coming up quickly,” Slootweg said in conversation with BioCentury's Stephen Hansen.
View full story: https://www.biocentury.com/article/659150
#EuropeanBiotech #VentureCapital #BiotechFunding #Bioeconomy #GlobalInnovation
00:00 - Introduction
01:34 - Forbion’s growth
05:35 - Deal flow in Europe
10:20 - Green Investing
14:24 - Sourcing Asia Deals
22:20 - Unlocking the EU’s Capital
27:54 - Speeding Up Trials
30:13 - Building a Thriving EU Market
34:38 - Central & Eastern Europe
Fler avsnitt av The BioCentury Show
Visa alla avsnitt av The BioCentury ShowThe BioCentury Show med BioCentury finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
